ERBB2 and breast cancer: Targeted therapy and immunotherapy are widely applied in other cancer types, such as anti-HER2 therapy in breast cancer [11] and immunotherapy with the monoclonal antibody durvalumab against programmed cell death ligand 1 (PD-L1) in non-small cell lung cancer [12].